<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   RhD alloimmunization in pregnancy: Overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       RhD alloimmunization in pregnancy: Overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        RhD alloimmunization in pregnancy: Overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth J Moise Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynne Uhl, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         RhD-negative patients who give birth to an RhD-positive newborn or who are otherwise exposed to RhD-positive red blood cells (RBCs) are at risk of developing anti-D antibodies. The RhD-positive fetuses/neonates of these mothers are at risk of developing hemolytic disease of the fetus and newborn (HDFN), which can be associated with serious morbidity or mortality. Where appropriate monitoring and intervention are available, HDFN can be treated successfully in most cases.
        </p>
        <p>
         Implementation of programs for antenatal and postnatal
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         prophylaxis has led to a significant reduction in the frequency of D alloimmunization and associated fetal/neonatal complications. However, D alloimmunization with serious sequelae in offspring still occurs, particularly in resource-limited countries where anti-D immune globulin is not widely available [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic provides an overview of RhD alloimmunization in pregnancy. Prevention and management of this disorder, as well as management of pregnancies with alloimmunization to other red cell antigens, are reviewed in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6802.html" rel="external">
          "RhD alloimmunization in pregnancy: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          THE Rh SYSTEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obstetric providers should be aware of the different Rh (formerly called Rhesus) phenotypes and their clinical implications [
         <a href="#rid2">
          2
         </a>
         ]. The following discussion is a synopsis of key clinical issues related to the Rh blood group system. A detailed discussion of this system, including its variants, can be found separately. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Rh blood group system'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H368020403">
         <span class="h2">
          D, d, C, c, E, e, and G
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard obstetric nomenclature for designating a pregnant individual's blood type is the ABO type and either "Rh positive" or "Rh negative." These terms are commonly used to describe an individual who has or does not have the D antigen on their red blood cells (RBCs). However, this abbreviated nomenclature is an artificial designation and can be confusing because the Rh blood group system consists of over 50 antigens [
         <a href="#rid3">
          3
         </a>
         ]; the most common antigens that induce antibodies are D, C, c, E, and e. There is no d antigen, but C and c and E and e are alternate alleles with codominant expression.
        </p>
        <p>
         Some combination of DCE is inherited as a haplotype from each parent. A pregnant person who is RhD negative can form anti-C, -c, -E, and/or -e antibodies if exposed to fetal RBCs with C, c, E, and/or e antigens inherited from the father that the mother does not share. Although an RhD-negative mother may have received prophylactic
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         , this would not prevent alloimmunization to other Rh antigens (c, C, E, e).
        </p>
        <p class="headingAnchor" id="H368020409">
         <span class="h2">
          Prevalence of RhD-negative blood type
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of the D antigen varies among populations. The following examples illustrate the variation in prevalence of phenotypically RhD-negative individuals in different populations [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basques – 30 to 35 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White North Americans or Europeans – 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Black or African Americans – 8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Africans – 4 to 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indians – 5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Native Americans and Inuit people – 1 to 2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Japanese – 0.5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thais – 0.3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chinese – 0.3 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H368020435">
         <span class="h2">
          Zygosity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 40 percent of RhD-positive individuals are homozygous for the D antigen (DD); the remainder are heterozygous (Dd).
        </p>
        <p class="headingAnchor" id="H368020441">
         <span class="h2">
          D variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         In White individuals, the primary molecular basis of the RhD-negative phenotype is absence of the D gene,
         <em>
          RHD
         </em>
         . In other phenotypically RhD-negative racial and ethnic groups, the D gene may be present but not translated or expressed [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Variants in the Rh system, particularly at the D and e loci, appear to be more common in populations of African descent. The RhD-negative phenotype in Africans is often the result of genes that contain sequences coding for D but do not produce the complete D antigen (ie,
         <em>
          RHD
         </em>
         pseudogene variant). The frequency of these gene distributions differs among Black African, African American, and Black South African individuals. An
         <em>
          RHD
         </em>
         pseudogene variant has been described in 69 percent of the Black South African population and 21 percent of the African American population [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Other unexpressed
         <em>
          RHD
         </em>
         gene variations have been observed in 12 percent of the Japanese population [
         <a href="#rid7">
          7
         </a>
         ]. These individuals have the entire
         <em>
          RHD
         </em>
         gene on their chromosomes but are RhD negative on serologic testing, and their RBCs are not affected by anti-D antibody in vivo.
        </p>
        <p>
         Depending on the reagent employed, some individuals undergoing D typing will reveal a "weak D" expression on initial testing. When the individual's RBCs are tested with an anti-D reagent, they have no or less than a 2+ reaction; when antihuman globulin is added, a moderate to strong reaction occurs. These individuals are called "serologic weak D phenotype" (formerly "Du positive"). The two main explanations for this finding are either a decreased number of intact D antigens on the surface of the RBCs ("weak D type") or D antigens that are missing a portion, called epitopes ("partial D phenotype").
        </p>
        <p>
         An estimated 0.2 to 1.0 percent of White individuals inherit
         <em>
          RHD
         </em>
         genes associated with the serologic weak D phenotype [
         <a href="#rid8">
          8
         </a>
         ]. Although more than 200 gene variants have been associated with alterations in the expression of the D antigen, the majority of weak D phenotypes (the proportion varies from 60 to 95 percent depending on the population) will be types 1, 2, or 3. Individuals with these three types who receive RhD-positive RBCs do not become alloimmunized to D. Other types of D variants can, however, form anti-D when exposed to the intact D antigen.
        </p>
        <p>
         Problems arise when an individual has undergone testing in one laboratory using a sensitive reagent that detects the weak D phenotype and reveals an RhD-positive result but is subsequently tested in a second laboratory using a less sensitive reagent that reports an RhD-negative result. This may occur when the individual is initially tested as a blood donor and then is subsequently retested as part of routine prenatal care. In the United States, the Association for the Advancement of Blood &amp; Biotherapies guideline for blood banks does not require performing a prenatal test for weak D or variant D, thus pregnant individuals with this blood type will be reported as RhD negative and should receive
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         , when indicated.
        </p>
        <p>
         A working group with representatives from the blood banking and obstetric community recommends that when discrepant D typing is noted or a weak D type is detected, the individual should undergo
         <em>
          RHD
         </em>
         genotyping for weak D types. If they are type 1, 2, or 3, they can be considered RhD positive, and
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         is not indicated. This would avert the need of almost 25,000 units of anti-D immune globulin being administered to 13,000 pregnant individuals. In addition, more than 47,000 units of RhD-negative RBCs (a scarce commodity in the blood bank) would not be transfused to these patients when they require transfusion [
         <a href="#rid9">
          9
         </a>
         ]. If the individual is genotyped and weak D types 1, 2, or 3 are not found, then they are managed as RhD negative, and anti-D globulin is indicated. (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients", section on 'Weak D or discordant D typing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H368020454">
         <span class="h2">
          G
         </span>
         <span class="headingEndMark">
          —
         </span>
         A change of a single amino acid in the extramembranous portion of both the D and C proteins results in the expression of the G phenotype [
         <a href="#rid10">
          10
         </a>
         ]. The majority of individuals who are D and/or C positive are also G positive; if both D and C are absent, G is also absent. Individuals who lack all three antigens can become alloimmunized to the C and G antigen while not developing antibodies to D.
        </p>
        <p>
         When an RhD-negative pregnant individual appears to have both anti-D and anti-C, the laboratory must determine whether the antibody is really anti-D or actually anti-G because a pregnant individual who develops anti-C and anti-G antibodies but no anti-D is still a candidate for
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         .
        </p>
        <p>
         Anti-G is usually found in combination with anti-D, anti-C, or both, and thus, its significance in HDFN is difficult to quantify. Identification of anti-G can be accomplished through sequential adsorption/elution procedures. Anti-G (not anti-D and anti-C) should be suspected when the anti-C titer is greater than or equal to the anti-D titer. (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3571754">
         <span class="h1">
          PATHOGENESIS OF ALLOIMMUNIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         By 38 days of gestation, the D antigen is expressed as part of the red blood cell (RBC) membrane [
         <a href="#rid11">
          11
         </a>
         ], and, in contrast to most other antigens (eg, A, B, M, N), D is only present on RBCs. Maternal D alloimmunization develops as a result of maternal immune system exposure to RhD-positive RBCs [
         <a href="#rid12">
          12
         </a>
         ]. Once
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         (Ig)G antibodies are present in the pregnant individual's circulation, they can cross the placenta and opsonize fetal RBCs, which are then phagocytized by macrophages in the fetal spleen, resulting in fetal anemia.
        </p>
        <p>
         Events that can cause maternal alloimmunization include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transplacental fetomaternal bleeding during any pregnancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Injection with needles contaminated by RhD-positive blood [
         <a href="#rid13">
          13-15
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadvertent transfusion of RhD-positive blood
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RhD-mismatched allogeneic hematopoietic stem cell transplantation [
         <a href="#rid16">
          16
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Transplacental fetomaternal bleeding accounts for virtually all cases of maternal D alloimmunization. Tiny (0.1 mL) quantities of fetal RBCs spontaneously gain access to the maternal circulation in nearly all pregnancies, as demonstrated by studies using flow cytometry [
         <a href="#rid17">
          17
         </a>
         ]. The frequency and volume of spontaneous fetomaternal bleeding increase with advancing gestational age and are highest at delivery [
         <a href="#rid18">
          18
         </a>
         ]. Fetomaternal bleeding can also be associated with events such as miscarriage, pregnancy termination, ectopic pregnancy, invasive in-utero procedures, fetal death, maternal abdominal trauma, antepartum maternal hemorrhage, and external cephalic version. Early predictors of fetomaternal bleeding remain largely unknown, and no cause can be identified in over 80 percent of cases [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Of note, there are at least six reports of alloantibodies to the D antigen without identifiable maternal exposure to RBCs carrying the D antigen [
         <a href="#rid20">
          20
         </a>
         ]. These cases may be the result of early pregnancy losses (including vanishing twins) that were not clinically recognized. Alternatively, a "grandmother theory" has been proposed as the etiology. In these cases, RBCs from the individual's heterozygous RhD-positive mother gain access to the fetal circulation at birth (maternal-fetal hemorrhage). The RhD-negative neonate then forms a low level of antibody to these RhD-positive cells.
        </p>
        <p>
         Although the D antigen is thought to elicit a strong immune response, the response varies considerably among individuals. As an example, studies in RhD-negative incarcerated males showed that intravenous injection of as little as 0.1 mL of RhD-positive RBCs was sufficient to immunize some individuals, while 30 percent of the RhD-negative males did not become sensitized despite two injections (first 10 mL, then 5 mL) of RhD-positive blood over a six-month period [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         The percentage of RhD-negative individuals developing an immune response to infusion of RhD-positive RBCs depends, in part, on the volume of blood infused: 0.5 mL RBCs stimulates an anti-D response in some subjects, whereas one unit (450 mL) of RBCs results in the maximum percentage of responders (80 percent) [
         <a href="#rid23">
          23
         </a>
         ]. The antibody response develops slowly and is usually not detectable serologically until 5 to 15 weeks after exposure.
        </p>
        <p>
         Whether a primary immune response occurs also depends upon several factors besides the volume of fetal blood to which the mother was exposed. These variables include the frequency of fetomaternal bleeding and whether the mother and fetus are ABO compatible [
         <a href="#rid12">
          12
         </a>
         ]. Both the immunogenicity of the fetal RBCs and the immunogenic response capacity of the mother play a role in pathogenesis. For example, individuals with acquired immune deficiency syndrome (AIDS), transplant patients on immunosuppressive medication, trauma victims, and cancer patients on intensive chemotherapy may not form alloantibodies to the D antigen [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H690423200">
         <span class="h1">
          FETAL/NEONATAL CONSEQUENCES OF ALLOIMMUNIZATION
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolytic disease of the fetus and newborn (HDFN)
         </strong>
         – Transplacental transfer of maternal antibody leads to HDFN. The severity of fetal anemia is influenced primarily by antibody concentration but also by additional factors that are not fully understood. These include the subclass and glycosylation of maternal antibodies; the structure, site density, maturational development, and tissue distribution of blood group antigens; the efficiency of transplacental IgG transport; the functional maturity of the fetal spleen; polymorphisms that affect Fc receptor function; and human leukocyte antigen (HLA)-related inhibitory antibodies [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5933.html" rel="external">
          "Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydrops fetalis
         </strong>
         – Hydrops fetalis (two or more of the following: skin edema, ascites, pericardial effusion, pleural effusion) in HDFN occurs when the fetal hemoglobin deficit is at least 7 g/dL below the mean for gestational age (consistent with a hematocrit less than approximately 15 percent or hemoglobin &lt;5 g/dL) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytopenia and neutropenia
         </strong>
         – HDFN may also be associated with thrombocytopenia and neutropenia [
         <a href="#rid27">
          27
         </a>
         ]. The risk increases with increasingly severe anemia and is most common in hydropic fetuses [
         <a href="#rid28">
          28
         </a>
         ]. In a systematic review, 11 to 26 percent of fetuses undergoing initial umbilical vein sampling because of D alloimmunization had platelet counts &lt;150,000/microL [
         <a href="#rid29">
          29
         </a>
         ]. However, severe thrombocytopenia (&lt;50,000/microL) is uncommon (prevalence 18 percent in one study). The mechanism of thrombocytopenia may be decreased production due to increased production of red blood cells (RBCs), but increased consumption or destruction of platelets has also been hypothesized.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3177059048">
         <span class="h1">
          SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         D typing and an antibody screen should be performed at the first prenatal visit. For RhD-negative individuals with an initially negative antibody screen and uncomplicated pregnancy, the antibody screen is repeated at approximately 28 weeks of gestation and at admission for labor and delivery [
         <a href="#rid30">
          30,31
         </a>
         ]. Screening can be performed with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         tube methods or less commonly by gel microcolumn. If the antibody screen is positive, the antibody titer is determined.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indirect Coombs
         </strong>
         – The indirect Coombs test is the most commonly used method for determining the titer. Incubation of known RhD-positive red blood cells (RBCs) with maternal plasma is the first step. Any anti-D antibody present will adhere to the RBCs, which are then washed and suspended in antihuman globulin (Coombs) serum. RBCs coated with maternal anti-D will be agglutinated by the antihuman globulin, which is referred to as a positive indirect Coombs test. The titer is the highest dilution at which agglutination occurs (eg, a 1:16 titer means the patient's plasma is positive at any dilution down to 1 part plasma to 15 parts diluent). Tube dilutions are set up to report titers of one to: 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, and 4096. Thus, for a patient with a titer of 1:4, a titer of 1:8 would represent a one tube increase and a titer of 1:16 would represent a two tube increase in titer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gel microcolumn assay (GMA)
         </strong>
         – The GMA card is used by an increasing number of blood banks to replace the traditional tube agglutination tests for identifying anti-D antibody and determining the titer. Advantages of GMA over tube tests include increased sensitivity, less susceptibility to interlaboratory and intralaboratory sources of variability, clear objective results that are stable, less time consuming, and compatible with automation [
         <a href="#rid32">
          32
         </a>
         ]. A major disadvantage is that a critical titer threshold has not been defined for gel method. Large prospective studies are needed to provide validation data correlating GMA results and tube titrations using a consistent technique and correlating GMA results and neonatal outcomes.
        </p>
        <p>
        </p>
        <p>
         Although not the primary test used for screening, the indirect Coombs titer (standard tube titer) is the value that should be used to guide obstetric management of alloimmunized pregnancies. GMA usually yields higher titer values than tube tests [
         <a href="#rid33">
          33,34
         </a>
         ]. In one review of 384 paired samples from eight studies, GMA results were 1.4 to 2 dilutions above tube results [
         <a href="#rid33">
          33
         </a>
         ]. The authors suggested that if a tube titer of 16 is considered critical, then a reasonable critical titer using GMA would be 64 because a two tube enhanced value is most common. However, they noted some studies reported GMA results as much as 5 additional dilutions above tube results and one reported GMA results were similar to tube results. Clinicians should therefore consult with their laboratory to determine the methodology used for antibody titration.
        </p>
        <p class="headingAnchor" id="H4158240897">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of D alloimmunization is based upon detection of anti-D antibody in maternal blood. Identification of an alloantibody means that the fetus is at risk for hemolytic disease of the fetus and newborn (HDFN), not that it has occurred or will develop.
        </p>
        <p class="headingAnchor" id="H1425064072">
         <span class="h2">
          False positive
         </span>
         <span class="headingEndMark">
          —
         </span>
         Screening for anti-D antibodies may not be helpful in identifying alloimmunization if the patient has received
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         within the past few weeks. Titration can be helpful in these cases: individuals who received anti-D immune globulin at 28 weeks will have a low (0 to ≤4) antibody titer at term; a titer &gt;4 suggests alloimmunization. Also, new alloimmunization is associated with IgM antibodies, whereas exogenous anti-D is IgG.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of pregnancies complicated by maternal alloimmunization involves the following principles [
         <a href="#rid35">
          35
         </a>
         ], all of which are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6802.html" rel="external">
          "RhD alloimmunization in pregnancy: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine the fetal RhD type. The fetal RhD type may be determined by testing fetal DNA in maternal serum, or it may be inferred if quantitative polymerase chain reaction (PCR) to identify the number of paternal
         <em>
          RHD
         </em>
         genes reveals homozygosity and paternity is assured.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitor for fetal anemia if the fetus is RhD positive. Monitoring depends on the clinical scenario and may involve following maternal anti-D titers in conjunction with ultrasound assessment of fetal middle cerebral artery peak systolic velocity (MCA-PSV).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Performing serial combined maternal plasmapheresis and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         therapy is a promising approach for decreasing the severity of fetal disease when there is a significantly elevated titer (eg, &gt;1024) or a history of previous severe hemolytic disease of the fetus and newborn (HDFN; eg, fetal or neonatal death due to HDFN or need for intrauterine transfusion [IUT] before 24 weeks of gestation) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If severe anemia is suspected on MCA-PSV, it should be confirmed by fetal blood sampling to determine the fetal hemoglobin/hematocrit level.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treat severe fetal anemia near term by delivery for neonatal treatment; remote from term (&lt;35 weeks gestation), perform intrauterine fetal transfusions.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          NEWBORN OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a report of hemolytic disease of the newborn detected, managed, and treated by the Regional Blood Transfusion Center of France over a 30-year interval, 62 percent of RhD-positive newborns of mothers with RhD alloimmunization underwent exchange transfusion [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         If the neonatal hematocrit is near normal because of a recent intrauterine transfusion (IUT), neonatal exchange transfusion may not be necessary. Serial bilirubin measurements with phototherapy when the phototherapy threshold is met are still warranted to prevent kernicterus [
         <a href="#rid38">
          38
         </a>
         ]. The use of intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is controversial and may be harmful [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
         With senescence of the transfused red cells, approximately 60 to 70 percent of newborns transfused in utero will require a "top-up" transfusion at one month of age due to suppression of fetal erythropoiesis from IUT and persistence of maternal antibody not removed by exchange transfusion. In these cases, a median of two top-up transfusions is necessary before reticulocytosis begins and maternally acquired anti-red blood cell antibodies disappear [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         A detailed discussion of the evaluation and management of neonates of alloimmunized mothers is available elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5933.html" rel="external">
          "Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most, but not all, D alloimmunization can be prevented by administration of
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         to females exposed or at high risk of being exposed to RhD-positive red blood cells (RBCs). (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients"
         </a>
         .)
        </p>
        <p>
         Once alloimmunization has occurred,
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         is not effective for preventing or reducing the severity of hemolytic disease of the fetus and newborn (HDFN). The three options for prevention of an affected fetus in this setting are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy by insemination with sperm from an RhD-negative donor
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In vitro fertilization and preimplantation genetic testing for selection of
         <em>
          RHD
         </em>
         -negative embryos (if father is heterozygous for
         <em>
          RHD
         </em>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of a gestational carrier
        </p>
        <p>
        </p>
        <p>
         Given the success of intrauterine fetal transfusion for treatment of HDFN, one of these options is usually considered only by individuals at risk for very early, severe fetal anemia in whom intrauterine fetal transfusion is more risky and less successful. (See
         <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">
          "Donor insemination"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7431.html" rel="external">
          "Gestational carrier pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5319429">
         <span class="h1">
          ALLOIMMUNIZATION OTHER THAN D
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis and management of pregnant individuals with alloimmunization to non-D red blood cell (RBC) antigens are reviewed separately [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3106448833">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121093.html" rel="external">
          "Society guideline links: Rh disease in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2668973526">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/87306.html" rel="external">
          "Patient education: Pregnancy in Rh-negative people (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rh system
         </strong>
         – The Rh blood system consists of the C, c, D, E, e, and G antigens (there is no d antigen). Variants include weak D and partial D antigens. In addition, the D gene may be present but not translated or not expressed. (See
         <a class="local">
          'The Rh system'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Typing and screening
         </strong>
         – RhD typing and an antibody screen are routine performed at the first prenatal visit. In RhD-negative individuals, the antibody screen should be repeated at 28 weeks of gestation and again at delivery. (See
         <a class="local">
          'Screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When discrepant RhD typing is noted or a weak D type is detected, the patient should undergo
         <em>
          RHD
         </em>
         genotyping for weak D types. If they are type 1, 2 or 3, they can be considered RhD positive and
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         is not indicated (see
         <a class="local">
          'D variants'
         </a>
         above). If genotype testing is not available, the patient should be treated as if they are RhD negative and administered anti-D immune globulin for standard indications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of D alloimmunization is based upon detection of anti-D antibody in maternal serum. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis of alloimmunization
         </strong>
         – Maternal D alloimmunization develops as a result of maternal immune system exposure to RhD-positive red blood cells (RBCs). Maternal immunization can occur as a result of transplacental fetomaternal hemorrhage during any pregnancy  (
         <a class="graphic graphic_table graphicRef55779" href="/z/d/graphic/55779.html" rel="external">
          table 1
         </a>
         ), injection with needles contaminated by RhD-positive blood, or inadvertent transfusion of RhD-positive blood (including during transplantation). (See
         <a class="local">
          'Pathogenesis of alloimmunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consequences
         </strong>
         – Transplacental transfer of maternal antibody leads to hemolytic disease of the fetus and newborn (HDFN). The severity of fetal anemia is influenced primarily by antibody concentration. Hydrops fetalis in HDFN occurs when the fetal hemoglobin deficit is at least 7 g/dL below the mean for gestational age. (See
         <a class="local">
          'Fetal/neonatal consequences of alloimmunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management of pregnancies complicated by maternal alloimmunization involves (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Determining the fetal RhD type by testing fetal DNA in maternal serum, or it may be inferred if quantitative polymerase chain reaction (PCR) to identify the number of paternal
         <em>
          RHD
         </em>
         genes reveals homozygosity and paternity is assured.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitoring for fetal anemia if the fetus is RhD positive. Monitoring may involve following maternal anti-D titers in conjunction with ultrasound assessment of fetal middle cerebral artery peak systolic velocity (MCA-PSV).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treating severe fetal anemia. Near term, the fetus is delivered for neonatal treatment; remote from term, intrauterine fetal transfusions are performed. Exchange transfusions may be required after birth. (See
         <a class="local">
          'Newborn outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Most, but not all, D alloimmunization can be prevented by administration of
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         to females exposed or at high risk of being exposed to RhD-positive RBCs. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013; 74 Suppl 1:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler SG, Li W, Langeberg A, Landy HJ. New laboratory procedures and Rh blood type changes in a pregnant woman. Obstet Gynecol 2012; 119:426.
          </a>
         </li>
         <li class="breakAll">
          Names for RH (ISBT 004) Blood Group Alleles. International Society of Blood Transfusion. http://www.isbtweb.org/fileadmin/user_upload/Working_parties/WP_on_Red_Cell_Immunogenetics_and/RHD_Partial_D_blood_group_alleles_v5.0_180207.pdf (Accessed on January 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed 2011; 96:F84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner FF, Gassner C, Müller TH, et al. Molecular basis of weak D phenotypes. Blood 1999; 93:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood 2000; 95:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003; 17:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garratty G. Do we need to be more concerned about weak D antigens? Transfusion 2005; 45:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler SG, Flegel WA, Westhoff CM, et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion 2015; 55:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000; 95:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergström H, Nilsson LA, Nilsson L, Ryttinger L. Demonstration of Rh antigens in a 38-day-old fetus. Am J Obstet Gynecol 1967; 99:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006; 46:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman J, Harman C, Manning F, et al. Intravenous drug abuse causes Rh immunization. Vox Sang 1991; 61:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lappen JR, Stark S, Gibson KS, et al. Intravenous drug use is associated with alloimmunization in pregnancy. Am J Obstet Gynecol 2016; 215:344.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markham KB, Scrape SR, Prasad M, et al. Hemolytic Disease of the Fetus and Newborn due to Intravenous Drug Use. AJP Rep 2016; 6:e129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cid J, Lozano M, Fernández-Avilés F, et al. Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases. Transfusion 2006; 46:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medearis AL, Hensleigh PA, Parks DR, Herzenberg LA. Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter. Am J Obstet Gynecol 1984; 148:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang 1986; 51:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroustrup A, Plafkin C, Savitz DA. Impact of physician awareness on diagnosis of fetomaternal hemorrhage. Neonatology 2014; 105:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudva GC, Branson KD, Grossman BJ. RhD alloimmunization without apparent exposure to RhD antigen. Am J Hematol 2006; 81:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zipursky A, Israels LG. The pathogenesis and prevention of Rh immunization. Can Med Assoc J 1967; 97:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollack W, Ascari WQ, Kochesky RJ, et al. Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion 1971; 11:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumpel BM. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 2002; 82:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boctor FN, Ali NM, Mohandas K, Uehlinger J. Absence of D- alloimmunization in AIDS patients receiving D-mismatched RBCs. Transfusion 2003; 43:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley AG. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transpl Immunol 2002; 10:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolaides KH, Thilaganathan B, Rodeck CH, Mibashan RS. Erythroblastosis and reticulocytosis in anemic fetuses. Am J Obstet Gynecol 1988; 159:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig JM, Christensen RD. Neutropenia and thrombocytopenia in infants with Rh hemolytic disease. J Pediatr 1989; 114:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Akker ES, de Haan TR, Lopriore E, et al. Severe fetal thrombocytopenia in Rhesus D alloimmunized pregnancies. Am J Obstet Gynecol 2008; 199:387.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbloom JI, Bruno AM, Conner SN, et al. Fetal thrombocytopenia in pregnancies complicated by fetal anemia due to red-cell alloimmunization: cohort study and meta-analysis. J Perinatol 2019; 39:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geaghan SM. Diagnostic laboratory technologies for the fetus and neonate with isoimmunization. Semin Perinatol 2011; 35:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol 2018; 131:e82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finck R, Lui-Deguzman C, Teng SM, et al. Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration. Transfusion 2013; 53:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman L, Andrews J, Evans MD, Cohn CS. Comparison of prenatal anti-D titration testing by gel and tube methods: A review of the literature. Transfusion 2021; 61:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adkins B, Maynie P, Chandler C, et al. Orthovision automated analyzers enable efficient and reproducible measurement of prenatal antibody titers though clinical correlation studies are necessary for clinical implementation. Transfusion 2017; 57:178A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwiers C, van der Bom JG, van Kamp IL, et al. Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 2018; 219:291.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moncharmont P, Juron Dupraz F, Vignal M, et al. Haemolytic disease of the newborn infant. Long term efficiency of the screening and the prevention of alloimmunization in the mother: thirty years of experience. Arch Gynecol Obstet 1991; 248:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smits-Wintjens VE, Walther FJ, Rath ME, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics 2011; 127:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos MC, Sá C, Gomes SC Jr, et al. The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. Transfusion 2013; 53:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Y, Pan JJ, Zhou XG, et al. The effect of immunoglobulin treatment for hemolysis on the incidence of necrotizing enterocolitis - a meta-analysis. Eur Rev Med Pharmacol Sci 2016; 20:3902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rath ME, Smits-Wintjens VE, Lindenburg IT, et al. Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease. Vox Sang 2011; 100:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008; 13:207.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6820 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24366465" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22270426" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : New laboratory procedures and Rh blood type changes in a pregnant woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22270426" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : New laboratory procedures and Rh blood type changes in a pregnant woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21037283" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The global burden of Rh disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9864185" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular basis of weak D phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10607679" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522770" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16181202" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Do we need to be more concerned about weak D antigens?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25438646" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10627438" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The Rh blood group system: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4962281" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Demonstration of Rh antigens in a 38-day-old fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16965599" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1763505" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intravenous drug abuse causes Rh immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26996989" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Intravenous drug use is associated with alloimmunization in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26989567" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hemolytic Disease of the Fetus and Newborn due to Intravenous Drug Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16441590" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6421161" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3095989" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fetomaternal transplacental hemorrhage during pregnancy and after delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24526231" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Impact of physician awareness on diagnosis of fetomaternal hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16493600" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : RhD alloimmunization without apparent exposure to RhD antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4168032" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The pathogenesis and prevention of Rh immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5002765" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12008036" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12559012" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Absence of D- alloimmunization in AIDS patients receiving D-mismatched RBCs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12216949" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3189438" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Erythroblastosis and reticulocytosis in anemic fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2494315" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Neutropenia and thrombocytopenia in infants with Rh hemolytic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18928982" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Severe fetal thrombocytopenia in Rhesus D alloimmunized pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31073147" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Fetal thrombocytopenia in pregnancies complicated by fetal anemia due to red-cell alloimmunization: cohort study and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21641488" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diagnostic laboratory technologies for the fetus and neonate with isoimmunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29470342" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22804101" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33797101" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Comparison of prenatal anti-D titration testing by gel and tube methods: A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Orthovision automated analyzers enable efficient and reproducible measurement of prenatal antibody titers though clinical correlation studies are necessary for clinical implementation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090532" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Management and prevention of red cell alloimmunization in pregnancy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29902448" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1910321" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Haemolytic disease of the newborn infant. Long term efficiency of the screening and the prevention of alloimmunization in the mother: thirty years of experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35927462" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422084" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22882285" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27735024" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The effect of immunoglobulin treatment for hemolysis on the incidence of necrotizing enterocolitis - a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20849463" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18396474" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fetal anemia due to non-Rhesus-D red-cell alloimmunization.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
